Organon backing satisfies Danish startup's funding needs for a new non-hormonal contraceptive

A new deal with US-based Organon, valued at as much as USD 370m, is enough for two founders to retain ownership of women’s health firm Cirqle Biomedical. No longer lacking funding, they can continue developing a non-hormonal contraceptive candidate.

Photo: Cirqle Biomedical

The two people behind Danish upstart Cirqle Biomedical, which is focused on women’s health, now have better future prospects after inking a partnership deal with US-based Organon last week.

Cirqle is founded, owned, and managed by Danish national Frederik Petursson Madsen and French national Thomas Crouzier, who are the firm’s chief executive and chief scientific officers, respectively.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs